Il-10 variant molecules and methods for treating inflammatory disease and oncology

Abstract

The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.

1 . A fusion protein of formula (I-VII)
   IL10-L 1 -X 1 -L 1 -X 2 -L 1 -IL10  (Formula I);
     (Z) n -X 1 -L 2 -Y 2 -L 1 -IL10  (Formula II);
     IL10-L 1 -Y 1 -L 2 -X 2 -(Z) n   (Formula III);
     X 1 -L 2 -X 2 -L 1 -IL10  (Formula IV);
     IL10-L 1 -X 1 -L 2 -X 2   (Formula V);
     X 1 -L 1 -IL10  (Formula VI);
     IL10-L 1 -X2  (Formula VII), or any combination thereof;
   
       wherein
 “IL-10” is a monomer sequence selected from SEQ ID Nos: 1, 3, 14, 15, 16, 18, 19, 55, 57, or 59; 
 “L 1 ” is a linker of SEQ ID No: 31 or 54; 
 “L 2 ” is a linker of SEQ ID No: 30; 
 “X 1 ” is a VH region obtained from a first antibody specific for epidermal growth factor receptor (EGFR); CD52; various immune check point targets, such as but not limited to PD-L1, PD-1, TIM3, BTLA, LAG3 or CTLA4; CD20; CD47; GD-2; HER2; EpCAM; ICAM (ICAM-1, -2, -3, -4, -5), VCAM, FAPα; 5T4; Trop2; EDB-FN; TGFβ Trap; MadCam, β7 integrin subunit; α4β7 integrin; α4 integrin SR-A1; SR-A3; SR-A4; SR-A5; SR-A6; SR-B; dSR-C1; SR-D1; SR-E1; SR-F1; SR-F2; SR-G; SR-H1; SR-H2; SR-I1; SR-J1; HIV, or Ebola; 
 “X 2 ” is a VL region obtained from the same antibody as X 1 ; 
 “Y 1 ” is VH region obtained from a second antibody specific for epidermal growth factor receptor (EGFR); CD52; various immune check point targets, such as but not limited to PD-L1, PD-1, TIM3, BTLA, LAG3 or CTLA4; CD20; CD47; GD-2; HER2; EpCAM; ICAM (ICAM-1, -2, -3, -4, -5), VCAM, FAPα; 5T4; Trop2; EDB-FN; TGFβ Trap; MadCam, β7 integrin subunit; α4β7 integrin; α4 integrin SR-A1; SR-A3; SR-A4; SR-A5; SR-A6; SR-B; dSR-C1; SR-D1; SR-E1; SR-F1; SR-F2; SR-G; SR-H1; SR-H2; SR-I1; SR-J1; HIV, or Ebola; 
 “Y 2 ” is a VL region obtained from the same antibody as Y 1 ; 
 wherein X and Y are obtained from the same or different antibody; 
 “Z” is a cytokine selected from IL-6, IL-4, IL-1, IL-2, IL-3, IL-5, IL-7, IL-8, IL-9, IL-15, IL-26, IL-27, IL-28, IL-29, GM-CSF, G-CSF, interferons-α, -β, -γ, TGF-β, or tumor necrosis factors -α, -β, basic FGF, EGF, PDGF, IL-4, IL-11, or IL-13; 
 “n” is an integer selected from 0-2. 
 
     
     
         2 . The fusion protein according to  claim 1 , wherein formula II and III are capable of forming a fusion protein complex where the IL-10 monomer from each of formula II and III are capable of forming a functional homodimeric IL-10 or variant thereof. 
     
     
         3 . The fusion protein according to  claim 2 , wherein formula II is SEQ ID Nos: 24, 26, 28, 41, 48, or 50. 
     
     
         4 . The fusion protein according to  claim 2 , wherein formula III is SEQ ID Nos: 25, 27, 29, 42, 49, or 51. 
     
     
         5 . The fusion protein according to  claim 2 , wherein the fusion protein complex is formed between SEQ ID Nos: 24 and 25; 26 and 27, 28 and 29; 41 and 42; 48 and 49; or 50 and 51. 
     
     
         6 . The fusion protein according to  claim 1 , wherein formula IV and V are capable of forming a fusion protein complex where the IL-10 monomer from each of formula IV and V are capable of forming a functional homodimeric TL-10 or variant thereof. 
     
     
         7 . The fusion protein according to  claim 6 , wherein formula IV is SEQ ID Nos: 35, 38, 46, 48, or 50. 
     
     
         8 . The fusion protein according to  claim 6 , wherein formula V is SEQ ID Nos: 36, 39, 47, 49, or 51. 
     
     
         9 . The fusion protein according to  claim 6 , wherein the fusion protein complex is formed between SEQ ID Nos: 35 and 36; 38 and 39, 46 and 47; 48 and 49; or 50 and 51. 
     
     
         10 . The fusion protein according to  claim 1 , wherein formula VI and VII are capable of forming a fusion protein complex where the IL-10 monomer from each of formula VI and VII are capable of forming a functional homodimeric IL-10 or variant thereof. 
     
     
         11 . The fusion protein according to  claim 1 , wherein formula I is SEQ ID Nos: 33-34, 40, 43-44, 45, 52 or 53. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . A method of treating cancer comprising administering to a patient in need thereof a composition comprising a fusion protein according to  claim 1 . 
     
     
         15 . The method according to  claim 14 , wherein the fusion protein is SEQ ID Nos: 28-29, 35-36, 38-39, 46-47, 52, 53, 61, 63, 65, or 67. 
     
     
         16 . The method according to  claim 15 , wherein the fusion protein forms a protein complex and the protein complex is formed between SEQ ID Nos: 28 and 29; 35 and 36; 38 and 39; or 46 and 47. 
     
     
         17 . The method according to  claim 14 , wherein the fusion protein comprises an IL-10 consisting of DV07 of SEQ ID No. 59. 
     
     
         18 . A method of treating inflammatory disease comprising administering to a patient in need thereof a composition comprising a fusion protein according to  claim 1 . 
     
     
         19 . The method according to  claim 17 , wherein the fusion protein is SEQ ID Nos: 26-27, 41-42, 48, or 49. 
     
     
         20 . The method according to  claim 18 , wherein the fusion protein forms a protein complex and the protein complex is formed between SEQ ID Nos: 26 and 27; 41 and 42; 48 and 49. 
     
     
         21 . The method according to  claim 18 , wherein the composition comprises a fusion protein of SEQ ID Nos: 37, 40, or 43. 
     
     
         22 . The method according to  claim 18 , wherein the fusion protein comprises an IL-10 consisting of DV06 of SEQ ID No. 57. 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled)